Clinical trials: Newly Diagnosed Multiple Myeloma
Myeloma
REal World MAIA UK OutcomEs
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated…
- Trial name
- REMAKE (NCT07532473)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Multiple Myeloma
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplant eligible patients with NDMM.
- Trial name
- NCT04935580
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Multiple Myeloma
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma…
- Trial name
- NCT05181501
- Testing
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Where
- 4 sites in China
- Volunteers
- 20 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
This is a multicenter, open label clinical trial evaluating the safety of the combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone) in newly diagnosed (ND) transplant…
- Trial name
- NCT04802356
- Testing
- Belantamab mafodotin, Bortezomib, Lenalidomide
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Plasma Cell Leukemia (PCL)
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
The goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma…
- Trial name
- CAREMM-011 (NCT07652905)
- Testing
- CM336, Isatuximab, Bortezomib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients
This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR…
- Trial name
- RP_MPR (NCT01160107)
- Testing
- RP followed by MPR
- Volunteers
- 46 people
- Sponsor
- Fondazione EMN Italy Onlus
Newly Diagnosed Multiple Myeloma (NDMM)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete…
- Trial name
- DURGA-6 (NCT07735637)
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed…
- Trial name
- NCT02219178
- Testing
- lenalidomide, Subcutaneous bortezomib, Dexamethasone
- Where
- 8 sites in Ireland
- Volunteers
- 42 people
- Sponsor
- Cancer Trials Ireland